Arcutis Biotherapeutics Inc Ordinary Shares ARQT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARQT is a good fit for your portfolio.
News
-
Arcutis Appoints David Topper as Chief Financial Officer
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
-
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
-
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
-
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $8.74
- Day Range
- $8.83–9.09
- 52-Week Range
- $1.76–15.16
- Bid/Ask
- $8.85 / $8.87
- Market Cap
- $1.02 Bil
- Volume/Avg
- 2,477 / 4.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.39
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 296
- Website
- https://www.arcutis.com
Comparables
Valuation
|
Metric
|
ARQT
|
TGTX
|
ALVR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.99 | — |
Price/Book Value | 9.76 | 13.44 | 0.59 |
Price/Sales | 10.39 | 9.06 | — |
Price/Cash Flow | — | 39.74 | — |
Price/Earnings
ARQT
TGTX
ALVR
Financial Strength
|
Metric
|
ARQT
|
TGTX
|
ALVR
|
|---|---|---|---|
Quick Ratio | 6.38 | 5.00 | 6.49 |
Current Ratio | 7.08 | 5.92 | 6.61 |
Interest Coverage | −7.72 | 2.04 | — |
Quick Ratio
ARQT
TGTX
ALVR
Profitability
|
Metric
|
ARQT
|
TGTX
|
ALVR
|
|---|---|---|---|
Return on Assets (Normalized) | −64.70% | 19.44% | −52.75% |
Return on Equity (Normalized) | −204.18% | 54.76% | −66.34% |
Return on Invested Capital (Normalized) | −65.35% | 35.76% | −59.54% |
Return on Assets
ARQT
TGTX
ALVR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wxlybpch | Zlph | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vxyznbk | Vnsthh | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mdtqkvmh | Jwklfc | $99.6 Bil | |
MRNA
| Moderna Inc | Pmxbrcfbq | Ldv | $38.8 Bil | |
ARGX
| argenx SE ADR | Hvskgxxv | Vpvq | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Xzfvbdqff | Mypl | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lsbqhkpl | Phqjym | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mvwlzyj | Fzldvc | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dmgxzcjff | Wdxgyq | $12.4 Bil | |
INCY
| Incyte Corp | Jgccgmb | Vqhtgw | $11.9 Bil |